No Picture
News

Halozyme Announces Roche Receives European Commission Approval For Phesgo® (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme’s ENHANZE® Technology For The Treatment Of Patients With HER2-Positive Breast Cancer

– Phesgo® Can be Administered in 5 to 8 Minutes Compared with Hours for the Standard Sequential IV Administration of Perjeta® and Herceptin® — First Subcutaneous Fixed-dose Combination of Two Monoclonal Antibodies Approved in Europe Utilizing Halozyme… […]

No Picture
News

Halozyme Announces Janssen Receives European Marketing Authorization For Subcutaneous DARZALEX® Utilizing Halozyme’s ENHANZE® Technology For The Treatment Of Patients With Multiple Myeloma

– Approval Follows Positive Opinion by European Committee for Medicinal Products for Human Use (CHMP) in April 2020 and Applies to All Current IV DARZALEX® Indications in Frontline and Relapsed/Refractory Settings — Innovative, Fixed-dose Subcutaneous… […]